Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis

Introduction to RejuvenAir^®

9 million Americans struggle with the debilitating symptoms of COPD with Chronic Bronchitis.¹ The RejuvenAir System offers a unique solution that is aimed at treating the underlying cause of the disease; something no drug or device on the market does today.

The RejuvenAir System is a revolutionary cryosurgical device which applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs through a minimally invasive, often outpatient or same-day bronchoscopic procedure.

^{1. American Lung Association.}

CAUTION: Investigational device. Limited by Federal law to investigational use.

About COPD with Chronic Bronchitis

Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).

Unlike common Bronchitis, which is acute and clears up quickly, Chronic Bronchitis (CB) is characterized by a long-term productive cough, breathlessness and/or wheezing as well as a tight chest sensation.

The persistent cough itself can be debilitating. Patients with Chronic Bronchitis often avoid social situations and give up activities, further contributing to a decline in overall well-being and quality of life. While current medications help alleviate symptoms, they don’t address the underlying cause of the disease and are largely ineffective.

Learn about our Clinical Trial

How Metered Cryospray Works

In Chronic Bronchitis patients, the airways have been damaged. Cilia, the tiny hair-like cells lining the lungs that help move mucus and debris out of the airway, become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

The RejuvenAir System delivers small, metered doses of cryogen spray which flash freeze the surface area of damaged airways. Diseased cells are destroyed, leaving behind the extra-cellular structure that allows for new healthy cells, including cilia and mucus-producing goblet cells, to repopulate.

RejuvenAir rejuvenates the airways.

How Metered Cryospray Works

-196° C flash freeze causes instant cell death

Preservation of extracellular matrix (ECM)

Intact ECM enables healing with limited scarring and fibrosis

In Chronic Bronchitis patients, the airways have been damaged. Cilia, tiny hair-like cells lining the lungs that help move mucus and debris out of the airway become dysfunctional, inducing an overabundance of goblet cells which over produce mucus. The combination of these factors contributes to inflammation, which makes it difficult to breathe.

RejuvenAir rejuvenates the airways.

The SPRAY-CB Clinical Trial

Researching a NEW option for people living with Chronic Bronchitis

The RejuvenAir System Trial for COPD with Chronic Bronchitis (SPRAY-CB) is currently recruiting patients in the United States. This trial is designed to continue to explore the safety and effectiveness of metered cryospray treatments in patients suffering from Chronic Bronchitis.

Participation in the SPRAY-CB Trial

If you are wondering whether you or somebody you know might qualify to participate in this trial, we invite you to answer a short questionnaire; after which, we will let you know whether you might be a suitable candidate.

For more information, refer to the ClinicalTrials.gov website. Details are available for the United States SPRAY-CB Study and a smaller European Study.

The RejuvenAir System is CE marked in the European Union and limited to investigational use in the United States and is currently not for sale.

Watch the video

Find out if you qualify

To proceed, select the participating study center nearest to you on the map. You will be taken to the www.spray-cb.com website. Here you can watch an educational video, complete a short questionnaire and, if qualified, register your details.

Title	Address	Description
Temple University	1801 N Broad St, Philadelphia, PA 19122, USA	ENROLLING Principal Investigator: Dr. G.J. Criner, Interventional Pulmonology /Pulmonary Care.
UC Davis Medical Center	2279 45th St, Sacramento, CA 95817, USA	ENROLLING Principal Investigator: Dr. Ken Yoneda, Interventional Pulmonology /Pulmonary Care
UT Southwestern Medical Center	5939 Harry Hines Blvd, Dallas, TX 75390, USA	ENROLLING Principal Investigator: Dr. Muhanned Abu-Hijleh, Interventional Pulmonology /Pulmonary Care
El Camino Hospital	701 E El Camino Real, Mountain View, CA 94040, USA	ENROLLING Principal Investigator: Dr. Ganesh Krishna, Interventional Pulmonology /Pulmonary Care
Beth Israel Deaconess Medical Center	185 Pilgrim Rd, Boston, MA 02215, USA	ENROLLING Principal Investigator: Dr. Adnan Majid, Interventional Pulmonology /Pulmonary Care
Sarasota Memorial Hospital	1700 S Tamiami Trail, Sarasota, FL 34239, USA	ENROLLING Principal Investigator: Dr. Joseph Seaman, Interventional Pulmonology /Pulmonary Care
Medical University of South Carolina	96 Jonathan Lucas St, Charleston, SC 29425, USA	ENROLLING Principal Investigator: Dr. Charlie Strange, Interventional Pulmonology /Pulmonary Care
Duke University School of Medicine	Durham, NC, USA	ENROLLING Principal Investigator: Dr. Wahidi, Interventional Pulmonology /Pulmonary Care
Advanced Pulmonary Research Institute	13005 Southern Blvd, Loxahatchee, FL 33470, USA	ENROLLING Principal Investigator: Dr. Warshoff, Interventional Pulmonology /Pulmonary Care
Henry Ford Hospital	2799 W Grand Blvd, Detroit, MI 48202, USA	NOT YET ENROLLING
INTEGRIS Health	3300 Northwest Expy, Oklahoma City, OK 73112, USA	NOT YET ENROLLING
Cooper Health	New Brunswick, NJ, USA	NOT YET ENROLLING
Christus St. Vincent Regional MC	Surgical Services, 455 St Michaels Dr, Santa Fe, NM 87505, USA	NOT YET ENROLLING
The Cleveland Clinic Foundation	9500 Euclid Ave, Cleveland, OH 44106, USA	NOT YET ENROLLING
University Of Wisconsin Hospital	Highland Ave, Madison, WI, USA	NOT YET ENROLLING
Louisiana State University Medical Center	Shreveport, LA 71103, USA	NOT YET ENROLLING
Ohio State University	Davis Heart and Lung Research Institute, 473 W 12th Ave, Columbus, OH 43210, USA	ENROLLING Principal Investigator: Dr. Christian Ghattas, Interventional Pulmonology /Pulmonary Care
Spectrum Health	4100 Lake Dr SE, Grand Rapids, MI 49546, USA	ENROLLING Principal Investigator: Dr. Cumbo-Nacelli, Interventional Pulmonology /Pulmonary Care
Johns Hopkins Hospital	600 N Wolfe St, Baltimore, MD 21287, USA	ENROLLING Principal Investigator: Dr. David Feller-Kopman, Bronchoscopy & Interventional Pulmonology

Find out if you qualify

To proceed, select the study center nearest to you from the list below . You will be taken to the www.spray-cb.com website. Here you can watch educational videos, complete a short questionnaire and, if qualified, register your details.

About Us

CSA Medical is committed to developing spray cryotherapy devices that improve the lives of people suffering from COPD with Chronic Bronchitis. We are advancing our core liquid nitrogen spray technology to target the underlying cause of Chronic Bronchitis – the over production of mucus and damaged cilia within the airways. By targeting and destroying these damaged cells without creating scar tissue, the body can begin the rapid regrowth of new, healthy normal functioning cells in the lung.

CSA Medical is currently conducting clinical studies with the RejuvenAir System. The clinical study aims to evaluate the effectiveness of the RejuvenAir System to reduce mucous production, cough, and inflammation in the Chronic Bronchitis patient population and to determine the extent of improvement in their overall health and quality of life.

News & Resources

CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis

May 13, 2021

These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...

CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis

Apr 19, 2021

Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...

CSA Medical Announces Metered Cryospray with the RejuvenAir® System for the treatment of Chronic Bronchitis Featured at the 21st World Congress of Bronchology and Interventional Pulmonology

Nov 23, 2020

The RejuvenAir System is designed to address the underlying cause of COPD with Chronic Bronchitis and enable rejuvenative healing of the airways BOSTON, Nov. 23, 2020 -- CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the...

More news & resources…

131 Hartwell Avenue
Lexington
Massachusetts 02421

Phone: 781.538.4720
Toll Free: 866.481.7786
Fax: 866.300.5183
Email: info@rejuvenair.com

CAUTION: Investigational device. Limited by Federal law to investigational use.

Beyond symptom relief, a breakthrough device designed to treat the underlying cause of COPD with Chronic Bronchitis